CERO Therapeutics Holdings, Inc. provided a corporate update on February 6, 2025, highlighting an improved cash balance and significant operational momentum. Following a recent $5 million financing, the company's current cash position stands at approximately $8 million, which is expected to fund numerous value-creating milestones.
The company also completed the conversion of the majority of its preferred shares into common shares, which is anticipated to significantly improve its capital structure. This move aims to streamline the company's financial standing moving forward.
CERO Therapeutics reported steady progress in the initiation of its Phase 1 clinical trial of CER-1236 in Acute Myeloid Leukemia (AML), with the first patient dosing expected in the first half of 2025. Additionally, the company anticipates submitting a second Investigational New Drug (IND) application to explore CER-1236 in breast and lung cancers in the coming months. The company also executed a 100:1 reverse stock split and established a pathway toward maintaining Nasdaq listing compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.